Table 1.
The demographic and clinical characteristics of HGSOC patients in the training and validation cohorts.
| Characteristic | Training cohort (n=182) | Validation cohort (n=79) | P-value |
|---|---|---|---|
| CA125, median (range) | 1471 (38.61, 6659.00) | 1415 (35.15, 5000) | 0.77 |
| Age, mean ± SD, years | 55.11 ± 8.90 | 56.6± 10.31 | 0.26 |
| NACT | 0.66 | ||
| Yes | 55 | 21 | |
| No | 127 | 58 | |
| Residual tumor | 0.99 | ||
| Yes | 49 | 22 | |
| No | 133 | 57 | |
| Ascites | 0.38 | ||
| <200ml | 58 | 21 | |
| 200ml-1000ml | 42 | 15 | |
| >=1000 | 82 | 43 | |
| LNM | 0.62 | ||
| Yes | 93 | 37 | |
| No | 89 | 42 | |
| FIGO Stage | 1.00 | ||
| Stage III | 123 | 54 | |
| Stage IV | 59 | 25 | |
| Progression-free survival | 0.25 | ||
| Yes | 152 | 71 | |
| No | 30 | 8 | |
| PFS time | 694 | 616 | 0.20 |
| Location | 0.30 | ||
| Unilateral | 52 | 17 | |
| Bilateral | 130 | 62 | |
| Diameter, mean ± SD, mm | 81.17±33.99 | 76.1±30.90 | 0.24 |